top of page

COVID-19 TREATMENT GUIDELINEIN TANZANIA, MARCH 2021

Posted by ULY CLINIC

24 Machi 2021 15:04:18

5.	RESPIRATORY MANAGEMENT FOR COVID-19 PATIENT

The guidance  is based on proper case management aspects intended for clinicians involved in the care of patients with suspected or confirmed COVID-19. It is not meant to replace clinical judgment or specialist consultation but rather to strengthen frontline clinical management and the public health response.

NOTE. THIS GUIDELINE IS THE POPERTY OF MINISTRY OF HEALTH, COMMUNITY DEVELOPMENT, GENDER, ELDERLY AND CHILDREN

5.	RESPIRATORY MANAGEMENT FOR COVID-19 PATIENT
5.	RESPIRATORY MANAGEMENT FOR COVID-19 PATIENT
5.	RESPIRATORY MANAGEMENT FOR COVID-19 PATIENT

5. RESPIRATORY MANAGEMENT FOR COVID-19 PATIENT

The cornerstone for the management of the hypoxaemia COVID-19 patient is the application of oxygen therapy via a variety of delivery methods and target SpO2 ≥90% in non-pregnant adults, titrating to reach targets by means of a nasal cannula, simple face mask or face mask with reservoir bag.

Give supplemental oxygen therapy immediately to patients with low oxygen saturation

Oxygen therapy is likely to be the single most effective supportive measure in COVID-19 patients. Target SpO2 ≥90% in non-pregnant adults and SpO2 ≥92% in pregnant patients. Children with emergency signs (obstructed or absent breathing, severe respiratory distress, central cyanosis, shock, coma or convulsions) should receive oxygen therapy during resuscitation to target SpO2 ≥94%; otherwise, the target SpO2 is ≥92%. Titrate oxygen therapy up and down to reach targets by means of a nasal cannula, simple facemask or facemask with reservoir bag, as appropriate.

1. Oxygenation and Ventilation

Non invasive oxygenation

• Low Flow nasal canula
• Simple face mask
• Non – rebreather Mask
• Cpap face mask
• Bag-valve mask (ambu bag)
• High Flow Nasal Canula

Invansive oxygenation

• Mechanical ventilating machine

a. Low Flow nasal canula

Indications/Descriptions

• For mild hypoxemia (SPO2- <94% >90%)
• Oxygen delivered 1-6lts/min
• Can deliver up to 22%-45% FiO2 on 1- 6L/min
• Higher rates of flow (>4L/min) may lead to nasal irritation

Source of oxygen

• Oxygen concentrator

OR

• Oxygen Cylinder

OR

• Central source from oxygen plant or manifold

Comments

• Clinical judgement should be used for the indication.

• Close monitoring is important for decision making of type of appliance to be used.

• General observation, by the use of the same appliance, there is much improvement on Cylinders rather than concentrator (when available) oxygen cylinder is a better option to concentrator

b. Simple face mask

Indications/Descriptions

• For moderate hypoxia (SPO2<89%
• Can deliver 40%-60% FiO2 on 6-10L/min
• Flow <5L/min does not flush out the CO2 in the mask.

Source of oxygen

• Oxygen concentrator

OR

• Oxygen Cylinder

OR

• Central source from oxygen plant or manifold

Comments

• Delivers an intermediated flow of oxygen (6-10lts/min
• Clinical judgement including respiratory rate (RR) should be used for the indication

c. Non – rebreather Mask

Indications/Descriptions

• Can provide 85%-95% FiO2 on 10- 15L/min.

Source of oxygen

• Oxygen Cylinder

OR

• Central source from oxygen plant or manifold

Comments

• Can deliver low and high flow oxygen

d. Cpap face mask

Indications/Descriptions

• These provide positive pressure or oxygen without need of intubation
• May be full-face mask or just covering nose and mouth.
• FiO2 is selected on the device (CPAP or ventilator machine)

Source of oxygen

• Oxygen Cylinder

OR
• Central source from oxygen plant or manifold.


Comments

• Delivers high flow oxygen.

• Indicated for complications like pulmonary oedema, it should be used regardless of the room condition (To avoid exposure to aerosols all healthcare workers should be on N95 and face shield.

• Clinical judgement, and patient’s response should be applied.

• Non-rebreather mask is superior to CPAP for oxygen delivery in COVID-19 patients.

e. Bag-valve mask (ambu bag)

Indications/Descriptions

• Has self-inflating bag, a valve and a mask
• Select the size according to age
• It provides positive pressure ventilation
• Procedure is called Bag valve-Mask Ventilation.
• Provides oxygen up to Fio2 of 100%

Source of oxygen

• Oxygen Cylinder

OR

• Central source from oxygen plant or manifold.


Comments

• Indicated for patients with signs of typical respiratory failure (no visible active breathing)
• Adherence to standard and additional IPC precautions should be applied.

f. Bag-valve mask (ambu bag)

Indications/Descriptions

• Can administer up to 10-60L of humidified warmed oxygen (2L/kg/min up to 12kg)
• Can be used in pediatric as well as adult patients

Source of oxygen

• Oxygen Cylinder

OR

• Central source from oxygen plant or manifold.

Comments

• Knowledge needed to set up pressure or volume required
• May be implemented and managed by non-ICU specialists outside ICU
• Does not require invasive monitoring
• Does not need as intensive nursing care as for invasive ventilation
• Can be combined with awake self- prone
• May be a lower-resource alternative to mechanical ventilation in some patient

g. High Flow Nasal Canula

Indications/Descriptions

• For failure of oxygenation or ventilation despite being kept on Bag Valve Mask Ventilation or CPAP
• Can provide FiO2 as selected on the machine, as well as positive pressure depending on setting done.

Source of oxygen

• Oxygen Cylinder

OR

• Central source from oxygen plant or manifold.

Comments

• It’s made for up to 100% oxygen delivery.
• Complicated, requires well trained staff and full ICU requirements.
• Standard and additional IPC precautions should be adhered during care of those patients.

2. Note

The use of the prone position in non-intubated, conscious patients who are hypoxemic may be beneficial. Patients who have respiratory failure despite maximal facemask oxygen should be promptly identified and evaluated for possible escalation of respiratory support. Possible modalities include high flow nasal cannula oxygen, continuous positive airway pressure, or intubation and mechanical ventilation.

3. Recognize severe hypoxemic respiratory failure

Recognize severe hypoxemic respiratory failure when a patient with respiratory distress is failing standard oxygen therapy.


Patients may continue to have increased work of breathing or hypoxemia (SpO2 <90%, PaO2 <60 mmHg [<8.0 kPa]) even when more than 10l/min oxygen is delivered via a face mask with reservoir bag. Hypoxemic respiratory failure in ARDS commonly results from intrapulmonary ventilation- perfusion mismatch or shunt and usually requires mechanical ventilation.

In the absence of an indication for endotracheal intubation, a trial of high-flow nasal oxygen (HFNO), continuous positive airway pressure (CPAP) or other non-invasive ventilation (NIV) technique may be considered for adults with Covid-19 and acute hypoxemic respiratory failure failing standard oxygen therapy.

Patients receiving HFNO, CPAP or other NIV should be in a closely monitored setting and cared for by experienced personnel capable of endotracheal intubation if the patient acutely deteriorates. Intubation should not be delayed in such circumstances.

Updated,

25 Machi 2021 07:24:57

References

1. THE UNITED REPUBLIC OF TANZANIA. MINISTRY OF HEALTH, COMMUNITY DEVELOPMENT, GENDER, ELDERLY AND CHILDRENCORONAVIRUS DISEASE 2019 (COVID-19) TREATMENT GUIDELINES. MARCH 2021

2. Del Rio, C. and P.N. Malani, (2020). 2019 Novel Coronavirus—Important Information for Clinicians. JAMA, 2020. 323(11): p. 1039-1040.

3. World Health Organization, (2020). Coronavirus disease 2019 (COVID-19) Situation Report 46, 2020.

4. World Confederation of Physical Therapists (WCPT) (2020). Physiotherapy management for COVID 19 version 1.0 23 March 2020

5. Sohrabi, C., Z. Alsafi, N. O'Neill, M. Khan, A. Kerwan, A. Al-Jabir, C. Iosifidis, and R. Agha, (2020). World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg, 2020. 76: p. 71-76.

6. Guan, W.-j., … Ye, C.-j. Zhu, S.-y. and Zhong N.-s., (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. NewEngland Journal of Medicine, 2020.

7. van Doremalen, N., … Lloyd-Smith, J.O., de Wit, E., and Munster, V.J., (2020). Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. New England Journal of Medicine, 2020.

8. Yoon, S.H., K.H. Lee, J.Y. Kim, Y.K. Lee, H. Ko, K.H. Kim, C.M. Park, and Y.H. Kim, Chest Radiographic and CT Findings of the 2019 Novel Coronavirus Disease (COVID-19): Analysis of Nine Patients Treated in Korea. Korean J Radiol, 2020. 21(4): p. 494-500.

9. Zhao, D., F. Yao, L. Wang, L. Zheng, Y. Gao, J. Ye, F. Guo, H. Zhao, and R. Gao, A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin Infect Dis, 2020.

10. Peng, Q.Y., X.T. Wang, L.N. Zhang, and G. Chinese Critical Care Ultrasound Study, Findings of lung ultrasonography of novel corona virus pneumonia during the 2019-2020 epidemic. Intensive Care Med, 2020.

11. Chen, N., M. Zhou, X. Dong, J. Qu, F. Gong, Y. Han, Y. Qiu, J. Wang, Y. Liu, Y. Wei, J. Xia,
T. Yu, X. Zhang, and L. Zhang, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020. 395(10223): p. 507-51s3.

12. Zhou, F., T. Yu, R. Du, G. Fan, Y. Liu, Z. Liu, J. Xiang, Y. Wang, B. Song, X. Gu, L. Guan, Y. Wei, H. Li, X. Wu, J. Xu, S. Tu, Y. Zhang, H. Chen, and B. Cao, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020.

13. Xie, J., Z. Tong, X. Guan, B. Du, H. Qiu, and A.S. Slutsky, Critical care crisis and some recommendations during the COVID-19 epidemic in China. Intensive Care Medicine, 2020.

14. Australian and New Zealand Intensive Care Society, ANZICS COVID-19 Guidelines, 202, ANZICS: Melbourne.

15. Kress, J.P. and J.B. Hall, (2014). ICU-acquired weakness and recovery from critical illness.
N Engl J Med, 2014. 370(17): p. 1626-35.

16. Herridge, M.S., C.M. Tansey, A. Matte, G. Tomlinson, N. Diaz-Granados, A. Cooper, C.B. Guest, C.D. Mazer, S. Mehta, T.E. Stewart, P. Kudlow, D. Cook, A.S. Slutsky, and A.M. Cheung, (2011). Functional disability 5 years after acute respiratory distress syndrome. N Engl JMed, 2011. 364(14): p. 1293-304.

17. Brouwers, M.C., M.E. Kho, G.P. Browman, J.S. Burgers, F. Cluzeau, G. Feder, B. Fervers,
I.D. Graham, S.E. Hanna, and J. Makarski, (2010). Development of the AGREE II, part 1: performance, usefulness and areas for improvement. Cmaj, 2010. 182(10): p. 1045-52.

18. Schunemann, H.J., …Cuello, R. Waziry,and Akl, E.A., (2017). GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. J Clin Epidemiol, 81: p. 101-110.

19. Moberg, J., A.D., …Morelli, G. Rada, and P. Alonso-Coello, (2018). The GRADE Evidence to Decision (EtD) framework for health system and public health decisions. Health Res Policy Syst, 16(1): p. 45.

20. Clinical Skills Development Service, Q.H. Physiotherapy and Critical Care Management eLearning Course. Accessed 21/3/20]; Available at https://central.csds.qld.edu.au/central/courses/108].

21. World Health Organisation, (2020). Infection prevention and control during health care when COVID-19 is suspected: Interim Guidance, M. 2020, Editor 2020.

22. Queensland Health,(2020). Clinical Excellence Division COVID-19 Action Plan: Statewide General Medicine Clinical Network,

23. The Faculty of Intensive Care Medicine. (2019). Guidelines for the provision of the intensive care services.; Available from: https://www.ficm.ac.uk/news-eventseducation/ news/guidelines-provision-intensive-care-services-gpics-%E2%80%93-secondedition.

24. Alhazzani, W., … Hayden, F., Evans, L., and Rhodes, A., (2019). Surviving sepsis campaign: Guidelines of the Management of Critically Ill Adults with Coronavirus Disease (COVID- 19). Critical Care Medicine, 2020. EPub Ahead of Print.

25. World Health Organization, (2020). Clinical Management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected Interim Guidance, 2020. p. WHO Reference number WHO/2019-nCoV/clinical/4.

26. Metro North, (2020). Interim infection prevention and control guidelines for the management of COVID-19 in healthcare settings,: https://www.health.qld.gov.au/ data/assets/pdf_file/0038/939656/qh-covid-19- Infectioncontrol- guidelines.pdf.

27. Stiller, K., (2013). Physiotherapy in intensive care: an updated systematic review. Chest,
144(3): p. 825-847.

28. Green, M., V. Marzano, I.A. Leditschke, I. Mitchell, and B. Bissett, (2016). Mobilization of intensive care patients: a multidisciplinary practical guide for clinicians. J Multidiscipline Health, 9: p. 247-56.

29. Hodgson, C.L. Zanni, L. Denehy, and S.A. (2014). Webb, Expert consensus and recommendations on safety criteria for active mobilization of mechanically ventilated critically ill adults. Critical Care, 2014. 18(6): p. 658.

30. Australian and New Zealand Intensive Care seeliery, ANCS COVID 19 Guidelines 202 ANZICS Melhsore.

31. Zanni, M.J., denehy,L.(2014). Expert consensus and recommendations on safety criteria for active mobilization of mechanically ventilated critically ill adults. Critical care. 18 (6): p 658.

bottom of page